AN INVESTIGATIONAL ORAL MICROBIOME DRUG, CP101, FOR THE PREVENTION OF RECURRENT C. DIFFICILE INFECTION: A RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL (PRISM3)

Jessica Allegretti  ¹     Colleen R. Kelly  ²     Thomas Louie  ³     Monika Fisher  ⁴     Susy Hota  ⁵     Bharat Misra  ⁶     Nicholas W Van Hise  ⁷     Eugene Yen  ⁸     Jeff S Bullock  ⁹     John Pullman  ¹⁰     Michael Silverman  ¹¹     Ian Davis  ¹²     Sarah McGill  ¹³     Shrish Budree  ¹⁴     Sahil Khanna  ¹⁵     Darrell Pardi  ¹⁵     Robert Orenstein  ¹⁶     Ari Grinspan  ¹⁷     Najwa El-Nachef  ¹⁸     Colleen Kraft  ¹⁹     Thomas J. Borody  ²⁰     Zain Kassam*  ^20    
1 Brigham & Women's Hospital, Boston, United States
² Warren Alpert Medical School of Brown University, Providence, United States
³ University of Calgary, Calgary, Canada
⁴ Indiana University, Indianapolis, United States
⁵ University of Toronto, Toronto, Canada
⁶ Borland Groover Clinic, Jacksonville, United States
⁷ Metro Infectious Disease Consultants, Burr Ridge, United States
⁸ NorthShore University HealthSystem, Evanston, United States
⁹ Southern Star Research Institute, San Antonio, United States
¹⁰ Mercury Street Medical, Butte, United States
¹¹ St. Joseph's Health Care, London, Canada
¹² Dalhousie University, Halifax, Canada
¹³ University of North Carolina Hospitals, Chapel Hill, United States
¹⁴ Finch Therapeutics, Somerville, United States
¹⁵ Mayo Clinic, Rochester, United States
¹⁶ Mayo Clinic, Scottsdale, United States
¹⁷ Mount Sinai Hospital, New York, United States
¹⁸ University of California San Francisco, San Francisco, United States
¹⁹ Emory University Hospital, Atlanta, United States
²⁰ Center for Digestive Diseases, Sydney, Australia

Topic
IBD

Session
Late breaking abstracts: GI inflammation and infection - From IBD to eosinophilic oesophagitis

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)